MRD Response-adapted Allo-HSCT for Adverse-risk AML

NCT06301425 · clinicaltrials.gov ↗
NA
Phase
RECRUITING
Status
178
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking University People's Hospital

Collaborators